Pacjenci
Czym jest alergia?
Alergia na roztocza kurzu domowego
Alergia na pyłki
Życie z alergią
Skutki społeczno-ekonomiczne
Czym jest astma alergiczna?
Jak diagnozuje się alergię?
Leczenie alergii
Pracownicy ochrony zdrowia
Leczenie alergii i astmy
Produkty
Reakcje niepożądane
Rozpoczęcie leczenia
Program badań klinicznych
Prace badawczo-rozwojowe
Zrozumieć immunoterapię
Plan prac badawczo-rozwojowych
Badania naukowe
Kariera
Praca w firmie ALK
Wolne stanowiska
O firmie ALK
ALK w skrócie
Produkcja
Obecność na całym świecie
Organizacja
Historia
Wartości
Właściciele
Media
ALK GBSC
About Us
News
Careers
Contact
Zgłaszanie działań niepożądanych
Fulltext search
Search
ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025
Read more
about ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025
Link
https://www.globenewswire.com/news-release/2025/06/16/3099778/0/en/ALK-presente…
Created date
Mon, 06/16/2025 - 12:00
Nasdaq ID
3099778
Last updated:
2025.06.16
ALK participates at Jefferies Global Healthcare Conference 2025 in New York
Read more
about ALK participates at Jefferies Global Healthcare Conference 2025 in New York
Link
https://www.globenewswire.com/news-release/2025/06/04/3093754/0/en/ALK-particip…
Created date
Wed, 06/04/2025 - 12:00
Nasdaq ID
3093754
Last updated:
2025.06.04
Three-month interim report (Q1) 2025 (unaudited)
Read more
about Three-month interim report (Q1) 2025 (unaudited)
Link
https://www.globenewswire.com/news-release/2025/05/06/3074684/0/en/Three-month-…
Created date
Tue, 05/06/2025 - 12:00
Nasdaq ID
3074684
Last updated:
2025.05.09
ITULATEK® approved for treatment of children and adolescents in Canada
Read more
about ITULATEK® approved for treatment of children and adolescents in Canada
Link
https://www.globenewswire.com/news-release/2025/05/08/3077431/0/en/ITULATEK-app…
Created date
Thu, 05/08/2025 - 12:00
Nasdaq ID
3077431
Last updated:
2025.05.08
ALK enters into neffy® co-promotion agreement in the USA
Read more
about ALK enters into neffy® co-promotion agreement in the USA
Link
https://www.globenewswire.com/news-release/2025/05/02/3073224/0/en/ALK-enters-i…
Created date
Fri, 05/02/2025 - 12:00
Nasdaq ID
3073224
Last updated:
2025.05.02
Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025
Read more
about Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025
Link
https://www.globenewswire.com/news-release/2025/04/29/3070453/0/en/Invitation-t…
Created date
Tue, 04/29/2025 - 12:00
Nasdaq ID
3070453
Last updated:
2025.04.29
ITULAZAX® tree pollen tablet approved for treatment of children in Europe
Read more
about ITULAZAX® tree pollen tablet approved for treatment of children in Europe
Link
https://www.globenewswire.com/news-release/2025/04/23/3066532/0/en/ITULAZAX-tre…
Created date
Wed, 04/23/2025 - 12:00
Nasdaq ID
3066532
Last updated:
2025.04.23
Grant of share-based long-term incentive instruments to members of the Board of Management and key employees
Read more
about Grant of share-based long-term incentive instruments to members of the Board of Management and key employees
Link
https://www.globenewswire.com/news-release/2025/04/03/3055331/0/en/Grant-of-sha…
Created date
Thu, 04/03/2025 - 12:00
Nasdaq ID
3055331
Last updated:
2025.04.03
Annual report 2024: ALK delivers 15% sales growth with profits up 65%
Read more
about Annual report 2024: ALK delivers 15% sales growth with profits up 65%
Link
https://www.globenewswire.com/news-release/2025/02/19/3028468/0/en/Annual-repor…
Created date
Wed, 02/19/2025 - 12:00
Nasdaq ID
3028468
Last updated:
2025.03.24
Annual General Meeting in ALK-Abelló A/S on 13 March 2025
Read more
about Annual General Meeting in ALK-Abelló A/S on 13 March 2025
Link
https://www.globenewswire.com/news-release/2025/02/19/3028793/0/en/Annual-Gener…
Created date
Wed, 02/19/2025 - 12:00
Nasdaq ID
3028793
Last updated:
2025.03.24
Pagination
First page
« First
Previous page
‹ Previous
Page
1
Page
2
Current page
3
Page
4
Page
5
Page
6
Page
7
Page
8
Page
9
…
Next page
Next ›
Last page
Last »
Subscribe to